Home Alzheimer’s Disease Model Provides Template for High-Income & Emerging Economies to Plan Cancer Surgery...

Model Provides Template for High-Income & Emerging Economies to Plan Cancer Surgery Provision

A guideline-based model described in The Lancet Oncology may provide a new template for high-income and emerging economies to rationally plan and evaluate their cancer surgery provision.

The model replicates examples of benchmarking radiotherapy and chemotherapy demand for cancer surgery across all major site-specific cancers. Investigators suggested the model could be used to identify service gaps at the population level after adjusting to the important local variations in cancer epidemiology.

“The model could also be used to estimate the future demand and the resource requirements for achieving country-specific benchmarks on cancer surgical service provision,” wrote the study authors, who were led by Sathira Kasun Perera, MSc.

In this study, investigators analyzed the latest clinical guidelines from high-income countries and charted surgical treatment pathways for 30 malignant…

Continue Reading to the Source


Please enter your comment!
Please enter your name here

Most Popular

Lower-Dose Hypofractionated Radiotherapy Schedule Proves Effective for Patients With Locally Advanced Bladder Cancer

Using a hypofractionated schedule of 55 Gy in 20 fractions over 4 weeks to treat patients with locally advanced bladder cancer was noninferior to...

Study Identifies New Biomarker Which Could Predict Response to CD40 Immunotherapy in Pancreatic Cancer

Research published in JCI Insight identified systemic inflammation as a possible resistance mechanism to a CD40–based chemoimmunotherapy in patients with advanced pancreatic cancer.1According to...

Significant Interfacility Variation Found in Implementation of Low-Value Breast Cancer Procedures

A number of facility-level characteristics were associated with the use of low-value breast cancer procedures, and interfacility variation presented an opportunity for formal de-implementation...

KarMMa Trial Results for Ide-Cel in Refractory Myeloma Show Favorable Efficacy

Chimeric antigen receptor (CAR) T-cell therapy with idecabtagene vicleucel (ide-cel) induced responses in almost 75% of patients with multiple myeloma following relpase on multiple...

Recent Comments